#United States #San Diego #SystImmune #BL-M11D1 #Acute Myeloid Leukemia

SystImmune, Inc. Gears Up for ASH 2024 Presentation

SystImmune, Inc., a biotechnology company that operates at the forefront of cancer treatment development, has announced plans to showcase its latest findings at the upcoming 2024 American Society of Hematology (ASH) Annual Meeting. The event is taking place from December 7-10 in San Diego, California.

The spotlight will be on SystImmune's new antibody-drug conjugate (ADC), BL-M11D1, specifically designed to target CD33, a clinically established marker for Acute Myeloid Leukemia (AML). This ADC is poised to make waves in the clinical landscape of cancer therapies, particularly for patients suffering from relapsed or refractory forms of this challenging disease.

SystImmune is set to present initial safety and efficacy data derived from a phase 1 clinical trial involving BL-M11D1. This presentation comes on the heels of encouraging preclinical results that highlighted its significant anti-tumor activity against CD33-expressing AML models. Dr. Jonathan Cheng, the Chief Medical Officer at SystImmune, expressed confidence in the treatment's potential, noting that its safety profile appears to be differentiated from current therapies, making it a vital option for those patients with limited treatment choices.

Understanding BL-M11D1

At the heart of this groundbreaking drug is its innovative construction, combining a monoclonal antibody component that binds specifically to CD33 with a powerful cytotoxic payload designed to eliminate cancer cells. This mechanism promotes antibody-dependent cellular cytotoxicity (ADCC), providing a dual impact of killing cancerous cells while also flagging them for immune system attack. This unique approach, combined with a stable enzyme-cleavable linker, underscores SystImmune's commitment to pioneering advanced cancer therapies.

Furthermore, the participation at the ASH Annual Meeting solidifies SystImmune’s position as a serious player in the oncology field. The scientific community and investors alike will be closely watching the outcomes of this presentation, as it may pave the way for the drug’s potential approval and subsequent use in combination therapies aimed at enhancing patient outcomes globally.

Event Details

The specific details for the poster presentation are as follows:

• - Title: BL-M11D1, a Novel CD33 Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory Acute Myeloid Leukemia
• - Speaker: Lin Song, from Tianjin, China
• - Publication Number: 4260
• - Session Name: 616 Acute Myeloid Leukemias Investigational Drug and Cellular Therapies Poster III
• - Session Date & Time: Monday, December 9th, 2024, from 6 PM to 8 PM PST
• - Location: San Diego Convention Center, Halls G-H

The abstract for this presentation is already accessible online and can be found on the ASH conference websites, providing further insights into the study's design and anticipated outcomes.

The Future of SystImmune

SystImmune is paving its own path within the biopharmaceutical landscape. With its base in Redmond, Washington, the company is engaged in the development of leading-edge therapies, from bi-specific antibodies to novel ADCs like BL-M11D1. Their pipeline is rich with assets currently undergoing clinical trials for both hematological malignancies and solid tumors, a testament to their robust R&D efforts.

As BL-M11D1 progresses through clinical trials, SystImmune remains optimistic about its broader therapeutic potential, including future applications in combination with other therapeutic agents to enhance efficacy and patient survival rates.

In conclusion, with the upcoming ASH presentation, SystImmune is strategically positioned to advance the narrative around AML treatment and to contribute meaningfully to the field of oncology, potentially revolutionizing standards of care in this space.